{"id":"avtx-803-l-fucose","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AVTX-803 delivers L-fucose to increase fucosylation of the Fc region of antibodies and glycoproteins on immune cells, which enhances antibody-dependent cellular cytotoxicity (ADCC) and natural killer cell engagement. This metabolic approach aims to boost the innate immune response against cancer cells by improving the binding affinity of antibodies to Fc receptors on immune effector cells.","oneSentence":"L-Fucose is a simple sugar that enhances the fucosylation of antibodies and immune cells to improve their effector functions and anti-tumor activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:12.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with monoclonal antibodies)"},{"name":"Hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT05754450","phase":"PHASE3","title":"An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II","status":"RECRUITING","sponsor":"AUG Therapeutics","startDate":"2023-04-10","conditions":"Leukocyte Adhesion Deficiency","enrollment":2},{"nctId":"NCT05462587","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II","status":"RECRUITING","sponsor":"AUG Therapeutics","startDate":"2022-07-28","conditions":"Leukocyte Adhesion Deficiency","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2259,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AVTX-803 (L-Fucose)","genericName":"AVTX-803 (L-Fucose)","companyName":"AUG Therapeutics","companyId":"aug-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-Fucose is a simple sugar that enhances the fucosylation of antibodies and immune cells to improve their effector functions and anti-tumor activity. Used for Advanced solid tumors (in combination with monoclonal antibodies), Hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}